<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157326</url>
  </required_header>
  <id_info>
    <org_study_id>10077</org_study_id>
    <secondary_id>H6D-MC-LVGU</secondary_id>
    <nct_id>NCT00157326</nct_id>
  </id_info>
  <brief_title>Tadalafil in Subjects With Mild to Moderate Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      Purpose: The primary objective of this study is to evaluate the efficacy and safety of&#xD;
      tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks&#xD;
      with mild to moderate hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measurement of this study is the mean change after 8 weeks of treatment from baseline in cuff seated trough diastolic blood pressure, cuff seated systolic blood pressures and automated blood pressure monitoring</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by evaluating all reported adverse events and changes in clinical laboratory values, ECGs, and vital signs</measure>
  </secondary_outcome>
  <enrollment type="Actual">180</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a documented medical history of hypertension.&#xD;
&#xD;
          -  Have cuff seated diastolic blood pressure values greater than or equal to 95 and less&#xD;
             than or equal to 104 mm at study entry&#xD;
&#xD;
          -  Have a negative serum pregnancy test at the time of enrollment and agree to use two&#xD;
             medically reliable methods of contraception until study completion, if female is of&#xD;
             child-bearing potential, between menarche and 1 year post menopause and not surgically&#xD;
             sterilized.&#xD;
&#xD;
          -  Are able to comply with study procedures and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have resistant hypertension or systolic hypertension.&#xD;
&#xD;
          -  Are obese, defined as having body mass index (BMI) greater than or equal to 35.&#xD;
&#xD;
          -  Are females who are pregnant or breast feeding.&#xD;
&#xD;
          -  Have a history of severe renal insufficiency or significant thyroid, renal or hepatic&#xD;
             disease.&#xD;
&#xD;
          -  Have a glycosylated hemoglobin A1c (HbA1c) greater than or equal to 10% during the&#xD;
             screening period.&#xD;
&#xD;
          -  Have significant anemia.&#xD;
&#xD;
          -  Have a significant or unstable cardiac history such as history of heart attack,&#xD;
             unstable angina, or stroke within 6 months of study entry, history of angina that was&#xD;
             treated with long- or short-acting nitrates within 90 days of study entry, history of&#xD;
             coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study&#xD;
             entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or&#xD;
             3rd-degree AV block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia,&#xD;
             a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history&#xD;
             of sudden cardiac arrest.&#xD;
&#xD;
          -  Have symptomatic heart failure requiring treatment, or significant disease of the&#xD;
             heart valves.&#xD;
&#xD;
          -  Have been treated for severe asthma, bronchospasm, or COPD within 3 months of study&#xD;
             entry.&#xD;
&#xD;
          -  Have severe peripheral vascular disease.&#xD;
&#xD;
          -  Have a documented diagnosis of sleep apnea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>October 23, 2007</last_update_submitted>
  <last_update_submitted_qc>October 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2007</last_update_posted>
  <keyword>High Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

